These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 22189229)

  • 1. [A case of local-recurring breast cancer under long term-treatment by capecitabine].
    Yoneyama K; Takeshita T; Suzuki H; Morise M; Suzuki T; Kishi S; Tsutsui A; Matsumoto A
    Gan To Kagaku Ryoho; 2011 Dec; 38(13):2623-5. PubMed ID: 22189229
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Prominent efficacy from capecitabine mono-therapy for a case with lymphangiosis carcinomatosa derived from recurrent breast cancer].
    Nozoe T; Mori E; Kono M; Iguchi T; Maeda T; Matsukuma A; Ezaki T
    Gan To Kagaku Ryoho; 2011 Mar; 38(3):427-9. PubMed ID: 21403447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Long-term response of liver metastases of breast cancer to capecitabine--case report].
    Macková D
    Klin Onkol; 2010; 23(1):46-8. PubMed ID: 20192074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [A case of recurrent breast cancer successfully treated with capecitabine monotherapy].
    Mitsuyama S; Anan K; Ono M
    Gan To Kagaku Ryoho; 2005 Aug; 32(8):1153-7. PubMed ID: 16121919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A woman with palmar and plantar hyperpigmentation].
    van Tienhoven G; Wilmink JW
    Ned Tijdschr Geneeskd; 2011; 155(45):A4100. PubMed ID: 22085578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single-agent capecitabine maintenance therapy after response to capecitabine-based combination chemotherapy in patients with metastatic breast cancer.
    Huang H; Jiang Z; Wang T; Zhang S; Bian L; Cao Y; Wu S; Song S
    Anticancer Drugs; 2012 Aug; 23(7):718-23. PubMed ID: 22739713
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A case of metastatic breast cancer with bilateral hydronephrosis effectively treated with capecitabine].
    Yamauchi S; Nakagawa T; Kasahara M; Sugimoto H; Ishiba T; Tamura N; Nagahara M; Sato T; Sugihara K
    Gan To Kagaku Ryoho; 2012 Nov; 39(12):2077-9. PubMed ID: 23267982
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Management of hand-foot syndrome in patient treated with capecitabine].
    Fujii C; Anami S; Fujino M; Yasui Y; Fujita M; Inoue M; Nakayama T; Kamigaki S; Tatsuta M; Furukawa H
    Gan To Kagaku Ryoho; 2008 Aug; 35(8):1357-60. PubMed ID: 18701848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Study of low-dose capecitabine monotherapy for metastatic breast cancer.
    Taguchi T; Nakayama T; Masuda N; Yoshidome K; Akagi K; Nishida Y; Yoshikawa Y; Ogino N; Abe C; Sakamoto J; Noguchi S;
    Chemotherapy; 2010; 56(2):166-70. PubMed ID: 20407245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant capecitabine combined with standard radiotherapy in patients with locally advanced rectal cancer: mature results of a phase II trial.
    Dunst J; Debus J; Rudat V; Wulf J; Budach W; Hoelscher T; Reese T; Mose S; Roedel C; Zuehlke H; Hinke A
    Strahlenther Onkol; 2008 Sep; 184(9):450-6. PubMed ID: 19016023
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An open-label, multicenter study of outpatient capecitabine monotherapy in 631 patients with pretreated advanced breast cancer.
    Venturini M; Paridaens R; Rossner D; Vaslamatzis MM; Nortier JW; Salzberg M; Rodrigues H; Bell R
    Oncology; 2007; 72(1-2):51-7. PubMed ID: 18004077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II study of second-line neoadjuvant chemotherapy with capecitabine and radiation therapy for anthracycline-resistant locally advanced breast cancer.
    Gaui MF; Amorim G; Arcuri RA; Pereira G; Moreira D; Djahjah C; Biasoli I; Spector N
    Am J Clin Oncol; 2007 Feb; 30(1):78-81. PubMed ID: 17278899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [A case of relapsed colon cancer successfully treated by capecitabine].
    Hashimoto T; Yokoyama M; Kimura S; Usuba O; Toyono M
    Gan To Kagaku Ryoho; 2013 Apr; 40(4):523-7. PubMed ID: 23848025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Capecitabine (Xeloda) as monotherapy in advanced breast and colorectal cancer: effectiveness and side-effects.
    Stathopoulos GP; Koutantos J; Lazaki H; Rigatos SK; Stathopoulos J; Deliconstantinos G
    Anticancer Res; 2007; 27(3B):1653-6. PubMed ID: 17595791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II trial of a novel capecitabine dosing schedule in combination with lapatinib for the treatment of patients with HER2-positive metastatic breast cancer.
    Gajria D; Gonzalez J; Feigin K; Patil S; Chen C; Theodoulou M; Drullinsky P; D'Andrea G; Lake D; Norton L; Hudis CA; Traina TA
    Breast Cancer Res Treat; 2012 Jan; 131(1):111-6. PubMed ID: 21898114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Capecitabine-induced hyperpigmentation].
    Vázquez-Bayo C; Rodríguez-Bujaldón AL; Jiménez-Puya R; Galán-Gutiérrez M; Moreno-Giménez JC
    Actas Dermosifiliogr; 2007 Sep; 98(7):491-3. PubMed ID: 17669305
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of age and overall survival in capecitabine-treated patients with metastatic breast cancer in clinical trials.
    Blum JL; Kohles J; McKenna E; Scotto N; Hu S; Odom D; Kaye JA; Glück S
    Breast Cancer Res Treat; 2011 Jan; 125(2):431-9. PubMed ID: 21042933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Study of tolerability of capecitabine in postoperative adjuvant chemotherapy in colon cancer].
    Matsuda C; Tamagawa H; Nishikawa K; Deguchi T; Kawata J; Iwase K; Takagi M; Fukui A; Nezu R; Tanaka Y
    Gan To Kagaku Ryoho; 2013 Mar; 40(3):327-30. PubMed ID: 23507593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced dose capecitabine is an effective and well-tolerated treatment in patients with metastatic breast cancer.
    El-Helw L; Coleman RE
    Breast; 2005 Oct; 14(5):368-74. PubMed ID: 16216738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial.
    Joensuu H; Kellokumpu-Lehtinen PL; Huovinen R; Jukkola-Vuorinen A; Tanner M; Kokko R; Ahlgren J; Auvinen P; Paija O; Helle L; Villman K; Nyandoto P; Nilsson G; Pajunen M; Asola R; Poikonen P; Leinonen M; Kataja V; Bono P; Lindman H
    J Clin Oncol; 2012 Jan; 30(1):11-8. PubMed ID: 22105826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.